Stoke Therapeutics STOK 深 沪
等待开盘 10-25 09:30:00 美东时间
31.86
+0.170
+0.54%
华盛通- 最 高32.46
- 今 开31.74
- 成交量 43.25万股
- 最 低 31.30
- 昨 收 31.69
- 总市值 17.46亿
- 52周最高 38.693
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.35
- 委 比 -71.08%
- 总股本 5479.74万
- 历史最高 71.58
- 量 比 0.48
- 振 幅 3.66%
- 历史最低 3.35
- 每 手 1
- 风险率 6.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stoke Therapeutics Unveils Two-Year Data Offering Hope For Patients With Rare Genetic Vision Disorder
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today announced the presentation of two-year data from the
10-20 19:36
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Biogen And Stoke Announce Phase 3 Zorevunersen Dosing Regimen Showed Continuing Improvements In Cognition And Behavior At 2 Years; Improvements In Overall Clinical Status At 3 Years In The Open-Label Extension Studies Reported By Clinicians And Caregivers In 95% Of Patients
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural
10-10 04:32
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Two-year data from zorevunersen's Phase 3 dose analysis showed sustained improvements in cognition and behavior in Dravet syndrome patients, contrasting minimal changes in natural history studies. Three-year results from open-label extension studies reported 95% of patients showing overall clinical improvement. Zorevunersen continues to demonstrate disease-modifying potential with reduced seizures and improved neurodevelopment. The ongoing Phase ...
10-09 20:30
Stoke Therapeutics Names Ian F. Smith CEO
Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial ExecutionArthur Tzianabos Resumes Chairman of the Board RoleBEDFORD, Mass.--(BUSINESS WIRE)--
10-06 19:36
Reported Earlier: Biogen And Stoke Therapeutics Report Durable Seizure Reductions And Cognitive Improvements With Zorevunersen In Dravet Syndrome; Zorevunersen Generally Well Tolerated Across All Studies; Data Support Pivotal Phase 3 EMPORER Study Now Underway
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –– Substantial increase in
09-02 21:56
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Zorevunersen, an investigational antisense oligonucleotide, shows potential as a disease-modifying therapy for Dravet syndrome, according to 3-year data from open-label extension studies. The studies demonstrate durable seizure reductions, improvements in cognition and behavior, and increased seizure-free days. Biogen Inc. and Stoke Therapeutics, Inc. announced the presentation of new clinical data at the 36th International Epilepsy Congress (IEC...
08-25 11:00
美股牛股 | Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray涨超30%
加密货币交易所Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray隔夜涨超30%，周内涨超90%，特朗普拟将大麻改为低危药物>>
08-14 15:08
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
